Vivtex's early low profile was a strategic choice to mature its technology and precisely define its value to partners. This 'figuring it out' period allowed them to avoid making a premature public splash with offerings they might later have to retract, ensuring a stronger, more coherent market entry.

Aphaia's scientific approach is so different from the mainstream that they couldn't rely on existing market understanding. Their co-founder actively toured conferences and participated in interviews to tell their story repeatedly. This educational campaign was crucial for building trust and getting stakeholders to "buy into" their completely new therapeutic concept.

Vivtex used stealth mode not for secrecy, but to give itself a 'time window' to fully develop its technology and nail down its precise application. This prevented them from making public promises they might later have to retract, ensuring a more stable and confident market entry.

In the rare disease space, success hinges on deep patient community engagement. Smaller, nimbler biotechs often excel at creating these essential personal ties, giving them a significant advantage over larger pharmaceutical companies.

A crucial piece of advice for biotech founders is to interact with patients as early as possible. This 'patient first' approach helps uncover unmet needs in their treatment journey, providing a more powerful and differentiated perspective than focusing solely on the scientific or commercial landscape.

Many biotechs focus R&D solely on regulatory approval. Beren Therapeutics integrates commercial thinking early to ensure clinical development answers a different question: Is what we're building meaningful to patients, payers, and providers? This de-risks the asset for commercial success, not just clinical milestones.

For well-funded founders, the downsides of PR can outweigh the benefits. Constant negative media attention is distracting for the team. Staying in deep stealth mode minimizes copycat competitors and keeps employees focused on innovation instead of public perception and damage control.

To escape public scrutiny after Uber, Travis Kalanick ran his new company, City Storage Systems, "full underground" for eight years. This extreme stealth, which included banning employees from listing the company on LinkedIn, was a deliberate strategy to build without media distraction.

Actuate Therapeutics demonstrates a patient-first ethos by having a dedicated group that not only helps patients access their own trials but also guides them to other companies' trials if those are a better fit. This builds community trust and prioritizes patient outcomes over proprietary interests.